share_log

Vertex Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Kewalramani Reshma

Vertex Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Kewalramani Reshma

福泰製藥 | 4:持股變動聲明-高管 Kewalramani Reshma
美股sec公告 ·  07/24 16:12
Moomoo AI 已提取核心訊息
Vertex Pharmaceuticals CEO & President, Kewalramani Reshma, completed a sale of 15,202 shares of the company's common stock on July 22, 2024. The transaction was executed at a price of $497.00 per share, resulting in a total sale value of $7,555,394. Following the sale, Reshma's direct holdings in Vertex Pharmaceuticals amount to 106,172 shares. The sale took place in an open market transaction, as reported in the company's filing.
Vertex Pharmaceuticals CEO & President, Kewalramani Reshma, completed a sale of 15,202 shares of the company's common stock on July 22, 2024. The transaction was executed at a price of $497.00 per share, resulting in a total sale value of $7,555,394. Following the sale, Reshma's direct holdings in Vertex Pharmaceuticals amount to 106,172 shares. The sale took place in an open market transaction, as reported in the company's filing.
福泰製藥的首席執行官和總裁Kewalramani Reshma於2024年7月22日出售了15,202股公司普通股。交易價格爲每股497.00美元,總銷售價值爲7,555,394美元。出售後,Reshma在福泰製藥的直接持股總量爲106,172股。此次銷售是在公開市場交易中進行的,如公司所述。
福泰製藥的首席執行官和總裁Kewalramani Reshma於2024年7月22日出售了15,202股公司普通股。交易價格爲每股497.00美元,總銷售價值爲7,555,394美元。出售後,Reshma在福泰製藥的直接持股總量爲106,172股。此次銷售是在公開市場交易中進行的,如公司所述。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息